Publications by authors named "A I Duran"
LIFE: A metric for mapping the impact of land-cover change on global extinctions.
Philos Trans R Soc Lond B Biol Sci
January 2025
Human-driven habitat loss is recognized as the greatest cause of the biodiversity crisis, yet to date we lack robust, spatially explicit metrics quantifying the impacts of anthropogenic changes in habitat extent on species' extinctions. Existing metrics either fail to consider species identity or focus solely on recent habitat losses. The persistence score approach developed by Durán .
View Article and Find Full Text PDFBackground: In triple-negative breast cancer (TNBC) patients receiving adjuvant capecitabine, the impact of HER2 expression on survival outcomes is unclear.
Methods: Between June 2017 and December 2023, 112 patients with TNBC who received adjuvant capecitabine due to residual masses after neoadjuvant chemotherapy (NACT) in three hospitals were identified. HER2 is analyzed through immunohistochemistry (IHC) and/or in situ hybridization in the core biopsy and/or post-surgical histopathologies.
Artificial Intelligence (AI) is an emerging tool that could be leveraged to identify the effective conservation solutions demanded by the urgent biodiversity crisis. We present the results of our horizon scan of AI applications likely to significantly benefit biological conservation. An international panel of conservation scientists and AI experts identified 21 key ideas.
View Article and Find Full Text PDFBackground/objectives: There is increasing evidence linking circulating neurotoxic lipids to the progression of chronic neuroinflammatory diseases in the peripheral and central nervous systems. Strategies to modify lipid profiles, such as docosahexaenoic acid (DHA)-rich supplementation, may aid in managing conditions like painful diabetic neuropathy (pDN). In a previous study, we demonstrated that three months of DHA supplementation significantly altered the metabolomic profile of patients with painful diabetic neuropathy (pDN), resulting in symptom improvement.
View Article and Find Full Text PDFArticle Synopsis
- Cardiac amyloidosis (CA) and coronary artery disease (CAD) can show similar symptoms, potentially leading to missed or delayed diagnoses of CA in acute care settings.
- A study analyzed data from 114 patients confirmed with cardiac amyloidosis, revealing that 25% had concurrent CAD; those with CAD were generally older and had higher rates of hypertension and dyslipidemia.
- The study concluded that while no significant differences in outcomes were found between the CA and CAD groups, further research is needed to improve the diagnosis of CA, especially in patients who also have CAD.